Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST, executive vice president and provost at Oregon Health and Science University, is receiving the award, which is presented to individuals who demonstrate excellence in pharmacy practice leadership.
Over the decades, the American Society of Health-System Pharmacists (ASHP) has been there during the career of Marie A. Chisholm-Burns, PharmD, PhD, MPH, MBA, FCCP, FASHP, FAST.
At this year’s ASHP Midyear Clinical Meeting & Exposition, Chisholm-Burns, executive vice president and provost at Oregon Health and Science University, will be receiving the ASHP Board of Directors’ Distinguished Leadership Award for her work in pharmacy practice leadership and academic pharmacy.
Transcript
What is the ASHP Board of Directors’ Distinguished Leadership Award, and what work have you done leading to you receiving this award at the 2023 ASHP Midyear Clinical Meeting & Exposition?
First, I want to thank ASHP Board of Directors for selecting me for the Distinguished Leadership Award. The award, to my understanding, is for individuals who have excellence in pharmacy practice leadership. I've done several things not only in pharmacy practice, but also in pharmacy practice leadership, including academic pharmacy, so I'm just honored.
ASHP is an organization that really means a lot to me. It's probably been there since the beginning with [my] residency training. I don't want to age myself here, but it's been decades that we have been friends and on this journey together. I also had the honor of being the founding chair, and now the past chair of the ASHP's new Section of Pharmacy Educators. And so that means a lot to me. It means a lot that ASHP has asked me to be involved in several things over the years.
So, that's a little bit about the award. I'm looking forward to receiving the award. My husband, John, is going to be there. And I'm just looking forward to seeing people again. I’m very excited about many things. Life is good.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
Prostate Cancer Studies Show Why Personalized Treatment, Trial Diversity Matter, Dorff Says
February 21st 2025Tanya B. Dorff, MD, medical oncologist and professor in City of Hope’s Department of Medical Oncology & Therapeutics Research, was a discussant for the TALAPRO-2 and STOPCAP trials at the opening session of ASCO GU.
Read More
Politics vs Science: The Future of US Public Health
February 4th 2025On this episode of Managed Care Cast, we speak with Perry N. Halkitis, PhD, MS, MPH, dean of the Rutgers School of Public Health, on the public health implications of the US withdrawal from the World Health Organization and the role of public health leaders in advocating for science and health.
Listen
NSCLC Advancements Offer Hope, but Disparities Persist
February 20th 2025Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing disparities in these populations.
Read More
Abortion in 2025: Access, Fertility, and Infant Mortality Updates
February 20th 2025While Republican state-led efforts aim to increase restrictions to abortion care and access to mifepristone and misoprostol in 2025, JAMA authors join the conversation with their published research and commentary.
Read More